Esperion Therapeutics, Inc. (ESPR) Financials
ESPR Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 205.8 million | 660.8 million |
2023-09-30 | 221.3 million | 631.3 million |
2023-06-30 | 234.6 million | 606.6 million |
2023-03-31 | 251.8 million | 581.5 million |
ESPR Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -37.1 million | 2.9 million |
2023-09-30 | -19.3 million | 3.0 million |
2023-06-30 | -24.8 million | 3.2 million |
2023-03-31 | -54.4 million | 2.9 million |
ESPR Net Income
No data available :(
ESPR Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | - | - | 4.6 million |
2023-09-30 | 114.8 million | - | 3.0 million |
2023-06-30 | 138.5 million | 260.7 million | 2.4 million |
2023-03-31 | 162.3 million | 260.3 million | 1.1 million |
ESPR Shares Outstanding
ESPR Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 17.7 million | 45.4 million | - |
2023-09-30 | - | 14.9 million | 33.2 million | - |
2023-06-30 | - | 22.1 million | 40.7 million | - |
2023-03-31 | - | 31.4 million | 41.6 million | - |
ESPR Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 32.3 million | 11.5 million |
2023-09-30 | 34.0 million | 13.4 million |
2023-06-30 | 25.8 million | 6.8 million |
2023-03-31 | 24.3 million | 11.7 million |
ESPR
Price: $2.08
52 week price:
Earnings Per Share: -2.03 USD
P/E Ratio: -1.14
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 623424
Ebitda: -37.8 millionMarket Capitalization: 465.4 million